CVE:VIV - Avivagen Stock Price, News, & Analysis

C$0.65
+0.03 (+4.84 %)
(As of 06/27/2019 04:05 AM ET)
Today's Range
C$0.65
Now: C$0.65
C$0.65
50-Day Range
C$0.55
MA: C$0.63
C$0.70
52-Week Range
C$0.33
Now: C$0.65
C$0.99
Volume3,000 shs
Average Volume51,746 shs
Market CapitalizationC$22.69 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Avivagen Inc. develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animal's own health defenses. The company offers products based on its OxC-Beta technology, such as OxC-beta Livestock, a premix for livestock feeds; and Vivamune Health Chews supplements for companion animals. The company was formerly known as Chemaphor, Inc. and changed its name to Avivagen Inc.in May 2012. The company is headquartered in Ottawa, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone613-949-8164

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$1.34 million
Cash FlowC$0.10 per share
Book ValueC($0.03) per share

Profitability

Miscellaneous

Employees13
Market CapC$22.69 million
Next Earnings Date9/3/2019 (Estimated)
OptionableOptionable

Receive VIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VIV and its competitors with MarketBeat's FREE daily newsletter.

Avivagen (CVE:VIV) Frequently Asked Questions

What is Avivagen's stock symbol?

Avivagen trades on the Canadian Venture Exchange (CVE) under the ticker symbol "VIV."

How were Avivagen's earnings last quarter?

Avivagen Inc (CVE:VIV) posted its earnings results on Monday, June, 3rd. The company reported ($0.04) EPS for the quarter. The company earned $303.98 million during the quarter. View Avivagen's Earnings History.

When is Avivagen's next earnings date?

Avivagen is scheduled to release their next quarterly earnings announcement on Tuesday, September 3rd 2019. View Earnings Estimates for Avivagen.

Has Avivagen been receiving favorable news coverage?

Media headlines about VIV stock have trended neutral this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avivagen earned a daily sentiment score of 0.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Avivagen.

Who are some of Avivagen's key competitors?

Who are Avivagen's key executives?

Avivagen's management team includes the folowing people:
  • Mr. G. F. Kym Anthony, Chairman, Interim CEO & Pres (Age 63)
  • Dr. Graham Burton, Co-Founder, Chief Scientific Officer & Director
  • Mr. Christopher Boland, Chief Financial Officer
  • Dr. Janusz Daroszewski, Co-Founder and Director of Product Devel. & Quality Assurance
  • Mr. Drew Basek, Director of Investor Relations

How do I buy shares of Avivagen?

Shares of VIV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Avivagen's stock price today?

One share of VIV stock can currently be purchased for approximately C$0.65.

How big of a company is Avivagen?

Avivagen has a market capitalization of C$22.69 million and generates C$1.34 million in revenue each year. Avivagen employs 13 workers across the globe.View Additional Information About Avivagen.

What is Avivagen's official website?

The official website for Avivagen is http://www.avivagen.com/.

How can I contact Avivagen?

The company can be reached via phone at 613-949-8164.


MarketBeat Community Rating for Avivagen (CVE VIV)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  7 (Vote Outperform)
Underperform Votes:  6 (Vote Underperform)
Total Votes:  13
MarketBeat's community ratings are surveys of what our community members think about Avivagen and other stocks. Vote "Outperform" if you believe VIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/27/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel